Wanted: A cure for capital market panic
This article was originally published in Scrip
My favourite biotech cartoon pictures a physician sitting at his desk holding a piece of paper and saying to his patient: "I don't usually recommend biotech shares but this one has come up with a cure for stock market panic." In recent weeks, the news that a number of venture capitalists are walking away the life sciences suggests an urgent unmet medical need for a capital market calming treatment.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.